INTRODUCTION
T RANSECTION OF THE OPTIC NERVE in adult rats induces neuronal death in approximately 80% of the retinal ganglion cells (RGCs) in 14 days (Villegas-Perez et al., 1993; Peinado-Ramon et al., 1996; Berkelaar et al., 1994) . It was proposed that the retrograde degeneration of axotomized RGCs is due to a lack of trophic factor supply upon disconnection from their target sites. This view is supported by experiments showing trophic fac-tors, including BDNF (Yan et al., 1999; Isenmann et al., 1998; Peinado-Ramon et al., 1996; Di Polo et al., 1998) ; GDNF (Yan et al., 1999) ; CNTF (Mey and Thanos, 1993; ; NGF (Lambiase et al., 1997; Rabacchi et al., 1994b) ; and NT4/5 (Peinado-Ramon et al., 1996; are able to delay RGC death following axotomy. Recent evidence has attributed the death of axotomized RGCs to apoptosis (Kermer et al., 1999b; Rabacchi et al., 1994a; Garcia-Valenzuela et al., 1994) . Interruption of the apoptotic pathway with agents like caspase inhibitor z-DEVD-cmk (Kermer et al., 1998 (Kermer et al., , 1999a or overexpression of bcl-2 in transgenic mice Porciatti et al., 1996; Bonfanti et al., 1996) augment the survival of axotomized RGCs. Oxidative stress has been implicated as one of the potent inducers and modulators of the apoptotic pathway in ischemia (Keller et al., 1998) and NMDA-induced retinal toxicity (Vorwerk et al., 1997; Castagne et al., 1999) . Thus, it is not unreasonable to speculate that antioxidants may offer neuroprotection to axotomized RGCs. In support of this hypothesis, intravitreal injections of the nitric oxide synthase (NOS) inhibitors, L-NAME and L-NOLA, enhance the survival of RGCs following axotomy (Ball and Keoberle, 1999) . These observations suggest that free radicals play a role in the etiology of axotomized RGC death, and thus, free radical scavengers may be neuroprotective for axotomized RGCs.
Extracts from American ginseng (Panax quinquefolius L.; Kitts et al., 2000) , Ginkgo biloba (Baudouin et al., 1999; Wei et al., 2000; Bastianetto et al., 2000a) and St. John's Wort (Hypericum perforatum; Tripathi and Pandey, 1999) have been demonstrated to exhibit antioxidant properties. In addition, these herbal extracts appear to offer neuroprotection in other models of injury. For example, saponins of Panax quinquefolius L. have been shown to delay neuronal death during ischemia (Attele et al., 1999; Wen et al., 1996) and glutamate-induced excitotoxicity (Kim et al., 1998) . Ginkgo biloba has also been observed to protect against ischemic injury (Pierre et al., 1999) , b-amyloid-induced toxicity (Bastianetto et al., 2000a) , nitric oxide-induced toxicity (Bastianetto et al., 2000b) , MPTP-induced nigrostriatal neuronal death (Wu and Zhu, 1999) , and light-induced photoreceptor damage (Ranchon et al., 1999) . Taken together, these studies suggest that Ginkgo biloba, Panax quinquefolius L., and Hypericum perforatum extracts may have neuroprotective effects in axotomy-induced RGC death. In the current communication, we examine the effects of these extracts, alone or in combination, on the survival of axotomized RGCs in adult hamsters. Since robust regeneration of damaged axons also requires survival of the parental neurons, agents that increase viability of axotomized RGCs may also promote the regrowth of their axons. Accordingly, we also investigate the effects of these herbal extracts on the capacity of axotomized RGCs to regenerate into a peripheral nerve graft, which provides a permissive environment for axonal regeneration (So and Aguayo, 1985) .
MATERIALS AND METHODS

Animals
A total of 112 adult golden hamsters (Mesocricetus auratus, 6-8 weeks old, weighing 60-80 g) were used in this study. Golden hamsters have been used in studies in which peripheral nerve grafts are attached to the ocular stump to induce long-distance regeneration (So and Yip, 2001; Cui et al., 1999) . The ability of the regenerated axons to form functional synapses has also been demonstrated by connecting the peripheral nerve grafts to targets such as the superior colliculus (Sauve et al., 2001; Sasaki et al., 1999) . Specific tests utilizing the orienting behavior exhibited by hamsters can then be performed to accurately examine functional recovery following axotomy (Carman and Schneider, 1992; Schneider, 1969) . The use of golden hamsters in this study therefore allows future investigation of the herbal extracts' ability to augment and restore visual performances. All operations were carried out in animals anesthetized with intraperitoneal injection of sodium pentobarbitone (Nembutal, Rhone Merieux Australia Pty Ltd., Australia; 50 mg/kg). Animals were weighed on the day of operation and on the day of sacrifice. The incidence of diarrhea and acute weight loss were monitored as indicators of the herbal extracts potential side effects as adverse reactions such as gastrointestinal problems, diarrhea and acute weight loss have been associated with HPE or PQE intake (Ernst et al., 1998; Vogler et al., 1999) . All animals were sacrificed with an overdose of anesthesia.
Extracts
Herbal extracts from CV Technologies (Canada, Edmonton, Alberta) were used in this study. The extracts were standardized by their biological activities and chemical compositions using ChemBioPrint™ technology, ensuring batch-to-batch consistency. Three extracts were used: (1) extract from the root of Panax quinquefolius L. (PQE), standardized to contain 25% ginsenosides; (2) Ginkgo biloba extract (GBE), standardized to contain 24% flavonoid glycosides and 6% terpenoids; and (3) Hypericum perforatum extract (HPE), standardized to contain 0.3% hypericin. Two herbal mixtures were constructed from these standardized extracts: (1) AD-FX, consisted of 80% PQE and 20% GBE by weight; and (2) CHEUNG ET AL.
Menta-FX, composed of 30.8% PQE, 61.5% HPE and 7.7% GBE by weight. All herbal potions (single extracts or mixtures) were suspended in sterile 0.01 M phosphatebuffered saline (PBS; pH 7.4) at concentrations specified in the following section, stored at 4°C and administered to animals within 2 weeks. The extracts were delivered directly into the esophagus of the animals with a specialized feeding cannula.
Herbal Extracts Treatment Scheme
In the survival studies, animals were divided into three groups: control (0.01 M PBS, n 5 10), single extracts treatment (n 5 53), and extract-mixtures treatment (n 5 21). Refer to Table 1 for detailed description of the treatment groups. Briefly, the single extract treatment group was divided into three subgroups. Animals received either PQE (10, 20, or 30 mg), GBE (2, 6, or 12 mg), or HPE (10, 20, and 30 mg). The extract-mixture treatment group was divided into two subgroups: 30 mg AD-FX and 30 mg Menta-FX. Animals were fed daily with 0.5 mL of vehicle or herbal extracts starting on the day of operation for 7 days. Animals were allowed to survive for 7 days postaxotomy before they were sacrificed.
In the regeneration studies (n 5 23), animals were divided into four groups (Table 1) . Animals were fed with 0.5 mL of vehicle (0.01 M PBS), 30 mg PQE, 30 mg AD-FX, or 30 mg Menta-FX per day for 21 days, starting on the day of operation. Animals were allowed to survive for 21 days postgrafting before they were sacrificed.
Optic Nerve Transection and Attachment of Peripheral Nerve Graft
In the survival studies (n 5 84), unilateral optic nerve transection was performed. A skin incision was made close to the superior orbital rim of the left eye. The left orbita was exposed and the superior extraocular muscles were excised to uncover the optic nerve. After opening the dural sheath, the optic nerve was completely transected at about 1.5 mm from the optic disc.
In the regeneration studies, an autologous peripheral nerve (PN) graft was attached to the ocular stump as a conduit for axonal regeneration. The optic nerve was transected 0.5 mm from the optic disc. A segment of the sciatic nerve (1 cm) was sutured onto the proximal stump of the optic nerve with a 10/0 suture. The distal end of the PN graft was secured on the connective tissue of the NEUROPROTECTION AND REGENERATION BY HERBAL REMEDY The respective amount of each of the single extracts in 30 mg of AD-FX and Menta-FX is listed.
skull using a 5/0 suture (So and Aguayo, 1985) . Care was taken to keep the blood supply to the retina intact throughout the operations. Animals with compromised blood supply after the operation were discarded.
Retrograde Labeling of Retinal Ganglion Cells and Labeled Retinal Ganglion Cells Counts
To assess the number of RGCs in normal retina, the optic nerve was transected in five animals. A Gelfoam (Upjohn, Kalamazoo, MI) soaked with 6% Fluoro-Gold (FG; Fluorochrome, Denver, CO) was placed at the cut site immediately after transection to label the RGCs. The animals were sacrificed 2 days later. Since optic nerve transection results in delayed cell death beginning on day 4 after axotomy (Berkelaar et al., 1994) , the number of RGCs labeled was assumed to be representative of the number of RGCs present in normal retinas.
In the survival studies, surviving RGCs were retrogradely labeled by placing a Gelfoam soaked with 6% FG at the ocular stump 2 days before sacrificing the animals. In the regeneration experiment, regenerating RGCs were labeled by injecting 1.5 mL of 6% FG into the distal end of the PN graft 3 days before the animals were killed. The left eye of the euthanatized animals in the normal, survival, and regeneration groups were enucleated, and the retinas dissected in 4% paraformaldehyde (PFA). Four radial cuts were made to divide the retinas into four quadrants (superiotemporal, superionasal, inferiotemporal and inferionasal). The retinas were then postfixed in 4% PFA for 45 min before they were flat-mounted with the RGC side up on gelatin-coated slides in 30% glycerin.
The slides were examined under fluorescence microscopy using an ultra-violet filter (excitation wavelength 5 330-380 nm). Labeled RGCs were counted along the median line of the four quadrants starting from the optic disc to the peripheral border of the retina at 500 mm intervals, under an eyepiece grid of 200 3 200 mm. The mean density of labeled RGCs in each retina was then multiplied by the area of the retina to obtain the number of labeled RGCs in the retina.
All data were expressed as mean 6 SD. Statistical significance was evaluated by one way ANOVA, followed by Tukey-Kramer post hoc test. Differences were considered significant for p , 0.05. Retinas that were poorly labeled were excluded from statistical analysis.
RESULTS
Effects of Optic Nerve Transection on the Number of Retinal Ganglion Cells
The number of RGCs labeled in normal retina was 65,890 6 5,684. Optic nerve transection led to a marked decrease in the number of surviving RGCs 7 days after axotomy in the PBS-treated group (21,841 6 3,536; Fig.  1 ). The morphology of the labeled RGCs was in accordance with that observed in previous studies (Peinado-Ramon et al., 1996; Koeberle and Ball, 1998) . FG fluorescence was found in the somata and proximal dendrites of the RGCs (Fig. 2A) . In addition to the labeled RGCs, microglia, characterized by their small spindle-shaped soma could also be identified (arrowhead, Fig. 2A ).
Effects of Single Extracts of PQE, GBE, and HPE on the Survival of Axotomized Retinal Ganglion Cells
Oral administration of PQE, GBE, and HPE for 7 days did not adversely affect the animals well-being. No diarrhea or acute weight loss was observed (data not shown). For the three dosages of PQE examined, treatment with 10 mg (23,999 6 3,099), 20 mg (23,634 6 6,659), or 30 mg (23,984 6 6,362) daily for 7 days had negligible effects on axotomized RGC survival (Fig. 1) . Daily administration of 10 mg (21,735 6 3,074), 20 mg (23,928 6 4,841), and 30 mg of HPE (25,044 6 2,634) resulted in slight enhancement of the number of surviving RGCs that appeared to be dose-related. The increase, however, was not significant (Fig. 1) . Treatment with 2 mg (24,434 6 1,692), 6 mg (23,065 6 3,883), and 12 mg of GBE (24,861 6 4,167) similarly did not significantly augment the number of surviving RGCs at 7 days after axotomy (Fig. 1) .
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FIG. 1. Effects of Panax quinquefolius L. extract (PQE; 10, 20, and 30 mg), Ginkgo biloba extract (GBE; 2, 6, and 12 mg), and Hypericum perforatum extract (HPE; 10, 20, and 30 mg) on the survival of axotomized retinal ganglion cells 7 days after axotomy. Note that none of the treatment significantly affected the number of surviving cells compared with that of the PBS-treated optic nerve transection (ONT) group.
Effects of AD-FX and Menta-FX on the Survival of Axotomized Retinal Ganglion Cells
No adverse reaction was observed following oral administration of AD-FX and Menta-FX for 7 days, with no incidence of diarrhea or acute weight loss (data not shown). Treatment with 30 mg of AD-FX per day (Fig.  2C ) caused a slight increase in the number of surviving RGCs (27,034 6 4,268; Fig. 3 ), although the enhancement was not statistically significant. However, daily treatment with 30 mg of Menta-FX (Fig. 2D ) significantly augmented the number of surviving RGCs (30,385 6 6,187; Fig. 3 ), rescuing 19% of the RGCs that would have died without treatment (p , 0.01; one-way ANOVA). 
Effects of PQE, AD-FX, and Menta-FX on Regeneration of Axotomized Retinal Ganglion Cells into Peripheral Nerve Graft
Attachment of PN graft to the optic nerve stump elicited approximately 5% of the RGCs to regrow their axons into the PN graft 21 days after axotomy (3,301 6 1,192; see Fig. 5 below) . As seen in Figure 4A , regenerating RGCs exhibited a characteristic hypertrophic morphology (Cui et al., 1999) that was drastically different from the surviving RGCs observed in Figure 2A . Treatment with 30 mg/day PQE (3,702 6 637) and 30 mg/day AD-FX (4,658 6 1,348) had no significant effects on the regenerative capability of the axotomized RGCs. Treatment with Menta-FX (Fig. 4D) , however, led to a significant increase in number of regenerating RGC (6,174 6 1,966; Fig. 5 ). This is a 87% enhancement in the number of regenerated RGCs compared with control (p , 0.05, one-way ANOVA).
DISCUSSION
In this study, we examined the effects of herbal extracts on axotomized RGCs. Our data showed that negligible neuroprotection was offered by PQE, GBE, and HPE treatment, despite previously demonstrated free radical scavenging capacity of the extracts in earlier studies. The apparent lack of action by these extracts could be due to poor absorption of extract components, although earlier studies suggest that HPE and GBE are well absorbed after ingestion (Franklin et al., 1999; Ranchon et al., 1999) . In addition, previous studies using oral administration of Panax quinquefolius L. saponins and EGb761 (a Ginkgo biloba extract) have shown that there is significant neuroprotection of damaged neurons in vivo (Wen et al., 1996; Pierre et al., 1999; Baudouin et al., 1999; Ranchon et al., 1999) , implying that the extracts components were absorbed and remained active.
Insufficient amounts of extract metabolites reaching the eye and/or the injury site may also result in the lack of neuroprotection by single extracts. The concentration of extract components required at the site of injury to rescue damaged neurons can vary depending on the type of injury and neuronal subtypes. For example, previous studies using lower doses of GBE than that adopted in the current study have been shown to provide effective neuroprotection in light-damaged photoreceptors (Ranchon et al., 1999) and ischemic cortical neurons (Pierre et al., 1999) . Despite the higher doses of GBE used in the present study, no protective effect was observed. Therefore, it is possible that a higher concentration of antioxidants is needed at the site of injury to protect RGCs from axotomy-induced death.
Other factors contributing to the lack of neuroprotection by single extracts may include the low concentration or absence of antioxidative ingredients in the extract preparations used in this study. The amount of active components in a herbal extract can vary depending on the strain of the herbs used. Different strains of ginseng, for example, have been demonstrated to contain different amounts of various ginsenosides (Chan et al., 2000; Wang et al., 1999) . The PQE preparation used in this study may hence lack or contain lower concentrations of various ginsenosides isolated from Panax ginseng, which have been demonstrated to be neuroprotective against ischemia (Attele et al., 1999; Wen et al., 1996) and glutamate-induced excitotoxicity (Kim et al., 1998) in neurons.
Finally, the treatment paradigm employed can also affect the effectiveness of the herbal extracts. Some of the previous studies with Ginkgo biloba extract involved pretreatment or co-treatment of the damaged neurons. However, in this study, treatment with PQE, HPE, and GBE did not commence until at least 2 h after the damage had been inflicted. This difference may contribute to the observed lack of neuroprotective effect of single extracts on axotomized RGCs. It should be noted, however, that studies by Bastianetto et al. have shown that post-injury treatment with EGb 761 can rescue neurons from nitric oxide-induced cell death (Bastianetto et al., 2000b) and b-amyloid-induced toxicity (Bastianetto et al., 2000a) . The time frame in which treatment need to commence may vary with the type of damage and neuronal subtypes. Experiments using a pretreatment paradigm will be helpful in resolving this problem.
A significant finding of this study is the neuroprotective effect exhibited by Menta-FX. The observation that the herbal extracts were only effective in combination suggests that the therapeutic values of herbal extracts can be maximized by mixing appropriate herbs together. Indeed, potency of a herbal remedy is often increased by using the whole extract, including the active ingredients and the supposedly inactive ingredients. For example, a study by Wu and Zhu (1999) has shown that EGb 761 prevents the decrease in dopamine levels in striatum following MPTP injection while the isolated compounds of EGb 761, ginkgolides A and B, do not. In addition, only ginseng extract can protect against ischemic neuronal death in gerbils, with ginsenosides Rb 1 , Rg 1 , and R0 being less effective or having no effects at all on mitigating the damage (Wen et al., 1996) .
The mechanisms involved in the neuroprotective effects of Menta-FX remain unknown. The neuroprotective property of Menta-FX may be a manifestation of the summation of free radical scavenging abilities of the different extracts. This is unlikely, however, given that high doses of PQE, GBE and HPE failed to provide equivalent neuroprotection offered by Menta-FX. On the other hand, Menta-FX may provide other neuroprotective properties aside from anti-oxidative capacity. Other potential mechanisms include (1) generation of novel neuroprotective compounds via chemical reactions among the ingredients of the extracts and (2) active compounds in the different extracts may act on different components of the apoptotic pathway involved in the death of axotomized RGCs. Menta-FX may directly inhibit activation of caspase-3 or -9, which have been demonstrated in axotomized RGCs (Kermer et al., 1999b) . Menta-FX may also offer neuroprotection by up-regulating production of trophic factors shown to enhance survival of axotomized RGCs, such as BDNF or CNTF (Yan et al., 1999; Isenmann et al., 1998; Peinado-Ramon et al., 1996; Di Polo et al., 1998; Mey and Thanos, 1993) . It is difficult to identify the pathways involved in the rescue effect of Menta-FX since the pharmacology of these extracts on injured neurons has not been completely elucidated. However, our observations suggest that two factors may play a role in Menta-FX's neuroprotective property. Note that AD-FX, a mixture of PQE and GBE, differs from Menta-FX, a mixture of PQE, HPE, and GBE, by the exclusion of HPE. The lack of significant rescue effect by AD-FX may suggest that (1) HPE is essential for the neuroprotective property of Menta-FX; or (2) all three of the extracts are required for the neuroprotective capability observed in Menta-FX. It remains to be clarified whether other combinations of the three herbal extracts such as HPE and GBE; or PQE and HPE, contribute to the neuroprotective effects of Menta-FX. In this study, treatment with PQE and AD-FX had negligible effects on the regeneration of axotomized RGCs. Treatment with Menta-FX, on the other hand, almost doubled the number of regenerating RGCs compared to that from the PBS-treated group (9.4% versus 5% of total RGCs). The mechanisms underlying Menta-FX's ability to augment regeneration of RGCs into a peripheral nerve graft are possibly related to its capacity to rescue axotomized RGCs. CNTF (Mey and Thanos, 1993; Cui et al., 1999) and aurintricarboxylic acid (Heiduschka and Thanos, 2000) have been demonstrated recently to enhance both survival and regeneration of axotomized RGCs. Similarly, Menta-FX may promote regeneration by increasing the number of surviving cells, hence permitting the regeneration-sensitive subpopulations of RGCs to survive long enough to extend their axons. PQE and AD-FX, which failed to significantly mitigate axotomy-induced RGC death also lacked the ability to enhance regeneration of axotomized RGCs. On the other hand, Menta-FX may also augment regeneration by modulating other parameters known to affect regenerative capacity. For example, Menta-FX may upregulate the expressions of proteins such as GAP-43, which was shown to precede robust regeneration of transected axons (Ng et al., 1995) . Menta-FX may also promote the synthesis of cytoskeletal components in axotomized RGCs to allow effective regeneration. In addition, it may change the behavior of growth cones to favor long-distance regeneration over limited local sprouting. Extrinsically, Menta-FX may neutralize the inhibitory environment surrounding the growing axons, such as the glial scar, to enable efficient regrowth of the axons (Grill and Tuszynski, 1999) . However, the precise actions of Menta-FX on these pathways remain to be uncovered by further experimentation.
In conclusion, the potential use of herbal extracts as neuroprotective agents for the injured RGCs is encouraging. Herbal extracts can be taken orally and possess minimal side effects. This is a significant advantage compared to drugs that are effective only when administered via an invasive route. In addition, the effectiveness of Menta-FX as a neuroprotective agent may be further increased by modifying the dosage used or the proportion of PQE, GBE and HPE in the mixture. Recent findings from our lab show that higher doses of Menta-FX further enhance the number of surviving RGCs at various time-points following axotomy. In addition, the duration of significant neuroprotection offered by Menta-FX can be extended using higher doses (unpublished observations). This suggests possible long-term neuroprotection by the herbal mixture.
This study holds important implications on the approach to take to enhance the therapeutic values of herbal extracts in neurodegenerative diseases or central nervous system trauma. We have demonstrated that a herbal extract-mixture exhibits neuroprotective effects on axotomized RGCs and increases regenerative propensity of the damaged axons. In addition, we showed that the therapeutic capacity of the herbal extracts is significantly augmented by using mixtures of the herbal extracts. We have established an easily-accessible and reproducible model for further investigations of the neuroprotective effect of these herbs. Fully explicating the precise interaction of these herbs will increase our understanding of the herbs and the mechanisms involved in the death & survival of axotomized RGCs.
